Literature DB >> 1925584

Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen.

C Y Wang1, D J Looney, M L Li, A M Walfield, J Ye, B Hosein, J P Tam, F Wong-Staal.   

Abstract

A titer for homologous viral neutralization activity (greater than 1:19,683) was observed after a 3.5-year immunization period with an octameric, branching peptide representing the principal neutralizing determinant (PND) of the human immunodeficiency virus-1IIIB envelope protein. Booster immunizations elicited persistent and potent antibodies in guinea pigs, exceeding responses produced by a conventional bovine serum albumin conjugate by 100-fold. Peptide length, central presentation of a conserved sequence, and inclusion of an upstream sequence contributed to immunogenicity. Titers (greater than 1:1,000) of heterotypic neutralizing antibodies also developed. Octameric PND peptides are a promising approach for an acquired immunodeficiency syndrome (AIDS) vaccine.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1925584     DOI： 10.1126/science.1925584

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  20 in total

1.  The Changing Epidemic of HIV.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

2.  Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

Authors:  T Muster; R Guinea; A Trkola; M Purtscher; A Klima; F Steindl; P Palese; H Katinger
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

3.  Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequences.

Authors:  A D Smith; D A Resnick; A Zhang; S C Geisler; E Arnold; G F Arnold
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

4.  Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: an information theoretic analysis.

Authors:  B T Korber; R M Farber; D H Wolpert; A S Lapedes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

5.  Large-scale sequence analysis of hemagglutinin of influenza A virus identifies conserved regions suitable for targeting an anti-viral response.

Authors:  Leepakshi Sahini; Anna Tempczyk-Russell; Ritu Agarwal
Journal:  PLoS One       Date:  2010-02-17       Impact factor: 3.240

6.  An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.

Authors:  Guangyu Zhao; Shihui Sun; Lanying Du; Wenjun Xiao; Zhitao Ru; Zhihua Kou; Yan Guo; Hong Yu; Shibo Jiang; Yuchun Lone; Bo-Jian Zheng; Yusen Zhou
Journal:  Virol J       Date:  2010-07-12       Impact factor: 4.099

7.  Sequence analysis of selected regions of the env (V3 loop and gp41) and gag (p7) reading frames of Ethiopian human immunodeficiency virus type 1 strains.

Authors:  S Ayehunie; B Johansson; A Sönnerborg; D W Zewdie; S Britton; O Strannegård
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 8.  HIV preventive vaccines. Progress to date.

Authors:  J Esparza; S Osmanov; W L Heyward
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

9.  Identification of B- and T-cell epitopes within the fibronectin-binding domain of the SfbI protein of Streptococcus pyogenes.

Authors:  Kai Schulze; Eva Medina; Gursharan S Chhatwal; Carlos A Guzmán
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

10.  An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.

Authors:  Guangyu Zhao; Yongping Lin; Lanying Du; Jie Guan; Shihui Sun; Hongyan Sui; Zhihua Kou; Chris Cs Chan; Yan Guo; Shibo Jiang; Bo-Jian Zheng; Yusen Zhou
Journal:  Virol J       Date:  2010-01-18       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.